Celadon Pharmaceuticals (LSE:CEL) Total Stockholders Equity : €3.67 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Total Stockholders Equity?

Celadon Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €3.67 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Celadon Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was €0.06. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Celadon Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 was 1.49.

Celadon Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Celadon Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Total Stockholders Equity Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

-0.13

0.11

8.83

3.67

Celadon Pharmaceuticals Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial			7.55	12.96	8.83	3.51	3.67

Celadon Pharmaceuticals (LSE:CEL) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Celadon Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3.666	-	0)	/	64.2089
	=	0.06

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Celadon Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.086	+	5.389)	/	3.666
	=	1.49

Celadon Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines